Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
about
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and BeyondBrivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence baseAnalgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy.Seizure control through genetic and pharmacological manipulation of Pumilio in Drosophila: a key component of neuronal homeostasisA Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Evaluation of brivaracetam: a new drug to treat epilepsy.Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide.Computational approaches for innovative antiepileptic drug discovery.Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).Will Brivaracetam Help My Patient? Only Time Will Tell.Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus.Epilepsy Treatment: A Futurist View.Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.A resurging boom in new drugs for epilepsy and brain disorders.Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.Brivaracetam: a novel antiepileptic drug for focal-onset seizures.A review of the pharmacology and clinical efficacy of brivaracetam.An RNAi-mediated screen identifies novel targets for next-generation antiepileptic drugs based on increased expression of the homeostatic regulator pumilio.
P2860
Q28068507-AC6E28F0-7DC7-4480-AA8A-D4B7E211F784Q28076065-F20F3F7D-515E-46EB-A5D9-FB9A66416BAEQ33621804-B68A8BE4-B293-4A7C-A16A-EDA603E9905CQ36244251-53B87637-1DAE-460B-8B60-F0C5B48C292DQ37092563-E988A6D7-B87A-4F25-8053-3FCB89121A96Q38614499-D4F519E1-994F-404D-852B-2B6EA6B91A5BQ38652806-7A8E2B32-2F12-4116-9121-680733877FABQ38904679-E98328C9-1215-4C2A-BE8A-41EE9E1750FAQ38907478-7D7687C9-4929-48F3-930E-46336CD49335Q38922348-441381D3-9700-4844-B1A0-A4BEBB616C96Q39006241-339D1503-49A8-4D6A-824E-BF2C8EB5BB92Q42317849-7D720200-B737-4A21-AF9F-5376BDD57D18Q46010938-188CF6BB-E447-4FB8-B1CB-EE1D8886CF63Q47114432-AD90D5F9-1735-439B-9912-4ED425B5985BQ47888971-3E52476A-2061-422A-B796-19D662DC7416Q48093388-F74A78C3-A4A4-446D-855A-3D9DD6CE7336Q48383809-8B8643A1-C9F6-408E-BC98-CC50775E2A9EQ49253776-2AAAF0B9-0372-46BE-A39E-F52D80738371Q49700507-8385C7AC-F3D7-4867-82DD-12A95A94BCDDQ52714753-059FA6E2-736F-486D-B4A9-A0238EA01EDB
P2860
Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Brivaracetam: Rationale for di ...... ligand for epilepsy treatment.
@en
type
label
Brivaracetam: Rationale for di ...... ligand for epilepsy treatment.
@en
prefLabel
Brivaracetam: Rationale for di ...... ligand for epilepsy treatment.
@en
P2093
P2860
P356
P1433
P1476
Brivaracetam: Rationale for di ...... ligand for epilepsy treatment.
@en
P2093
Alain Matagne
Benoit Kenda
Christian Wolff
Henrik Klitgaard
Isabelle Niespodziany
Jean-Marie Nicolas
Jonas Hannestad
Karine Leclercq
Marc De Ryck
Martyn Wood
P2860
P304
P356
10.1111/EPI.13340
P577
2016-02-26T00:00:00Z